Patients in the study, who took the drug as needed for up to seven nights per week, did not experience rebound insomnia after treatment with the drug was discontinued.
This evaluation of Ambien CR 12.5mg involved 1,018 adult volunteers who were studied for a period of 25 weeks. The objective was to evaluate the long-term safety and efficacy of Ambien CR taken as needed up to seven nights per week.
According to the data, Ambien CR demonstrated significant improvements in total sleep time, sleep onset latency, wake time after sleep onset, sleep quality, and number of awakenings versus placebo.
“These data are important for patients who experience chronic insomnia because they demonstrate there is a treatment option in Ambien CR that can be taken safely and effectively as needed long-term to help them both fall asleep and maintain sleep through the night,” said Dr Tom Roth, director of the Sleep Disorders Center at Henry Ford Hospital.
The data were presented at the Collegium Internationale Neuro-Psychopharmocologicum (CINP) 25th biennial congress in Chicago.